- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06771219
Un estudio de fase 1 de aumento de dosis de SLV 154 en sujetos con tumores sólidos metastásicos
This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
A Bayesian optimal interval (BOIN) design with a target dose-limiting toxicity (DLT) rate for the maximum tolerated dose (MTD) of 27% and an estimated maximum sample size of ~70 subjects will be used to guide the dose escalation and determine the recommended dosing regimen (RDR) of SLV-154. Once the initial RDR is established in the Phase 1a portion of this study, further development in the Phase 1b expansion portion of this study will be considered in patients with specific cancers. In the Phase 1b part of this study, enrollment of each tumor-specific cohort will be performed using a Simon 2-stage optimal design.
SLV-154 will be administered intravenously (IV) in repeated 3-week cycles. Treatment will continue until progressive disease or discontinuation.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Langdon L Miller, MD
- Número de teléfono: 908-906-6471
- Correo electrónico: lmiller@solvetx.com
Copia de seguridad de contactos de estudio
- Nombre: Hong Ren, MD
- Número de teléfono: 425-894-2558
- Correo electrónico: hren@solvetx.com
Ubicaciones de estudio
-
-
California
-
Newport Beach, California, Estados Unidos, 92663
- Reclutamiento
- Hoag Memorial Hospital Presbyterian
-
Contacto:
- Cindy Do, BSN, RN
- Número de teléfono: 949-764-4624
- Correo electrónico: cindy.do@hoag.org
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- Washington University
-
Contacto:
- Sara Mitchum
- Número de teléfono: 314-273-8602
- Correo electrónico: saram@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816
- Reclutamiento
- Astera Cancer Care
-
Contacto:
- Percy Yeung
- Número de teléfono: 732-387-3378
- Correo electrónico: percy.yeung@asterahealthcare.org
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Memorial Sloan Kettering Cancer Center
-
Contacto:
- Roisin O'Cearbhaill, MD
- Número de teléfono: 646-888-4227
- Correo electrónico: ocearbhr@mskcc.org
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Reclutamiento
- University Hospitals Cleveland Medical Center
-
Contacto:
- Afshin Dowlati, MD
- Número de teléfono: 212-844-6031
- Correo electrónico: afshin.dowlati@UHhospitals.org
-
Columbus, Ohio, Estados Unidos, 43210
- Reclutamiento
- The James Outpatient Care West Center
-
Contacto:
- Adam Roan
- Número de teléfono: 614-685-0587
- Correo electrónico: Adam.Roan@osumc.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19111
- Reclutamiento
- Fox Chase Cancer Center
-
Contacto:
- Dajah White-Dumpson
- Número de teléfono: 215-214-1600
- Correo electrónico: Dajah.White-Dumpson@fccc.edu
-
Contacto:
- Shannon Fabrie
- Número de teléfono: 215-728-3620
- Correo electrónico: shannon.fabrie@fccc.edu
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
Contacto:
- Rabia Khan
- Número de teléfono: 713-563-4667
- Correo electrónico: RKhan@mdanderson.org
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Oncology Consultants
-
Contacto:
- Julio Peguero, MD
- Número de teléfono: 713-600-0900
- Correo electrónico: jPeguero@oncologyconsultants.com
-
San Antonio, Texas, Estados Unidos, 78229
- Reclutamiento
- Mays Cancer Center; University of Texas Health San Antonio
-
Investigador principal:
- Daruka Mahadevan
-
Contacto:
- Daruka Mahadevan, MD
- Número de teléfono: 210-450-1000
- Correo electrónico: mahadevand@uthscsa.edu
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- University of Washington / Fred Hutchinson Cancer Center
-
Contacto:
- Phase 1 Clinical Trials
- Número de teléfono: 206-606-7551
- Correo electrónico: phase1clinicaltrial@fredhutch.org
-
Tacoma, Washington, Estados Unidos, 98405
- Reclutamiento
- Northwest Medical Specialties, PLLC
-
Contacto:
- CarrieAnn Brown
- Número de teléfono: 253-428-8700
- Correo electrónico: cbrown@nwmsonline.com
-
Contacto:
- Kiersten Peart
- Número de teléfono: 253-428-8700
- Correo electrónico: kpeart@nwmsonline.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Men or women (as appropriate for cancer type) of age ≥12 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed diagnosis of advanced cancer as documented in medical records.
- Presence of metastatic or recurrent locally advanced cancer.
- Presence of radiographically measurable disease.
- Prior receipt of one or more commercially available therapies that are indicated within product labelling or recommended under current guidelines as appropriate treatment for the subject's cancer (unless evolving data support application of SLV-154 in previously untreated subjects with high unmet medical need and inadequate and/or poorly tolerated treatment options).
- Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.
- Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and/or fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.
- Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.
- Adequate hematological profile.
- Adequate coagulation profile.
- Adequate hepatic profile.
- Adequate renal function.
- Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.
- For female subjects of childbearing potential, a negative serum pregnancy test.
- For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.
- For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.
- Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy/aspirations and/or radiographic studies), and study restrictions.
- Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.
Exclusion Criteria:
- Unstable malignancy involving the central nervous system.
- Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.
- Significant cardiovascular event or comorbidity.
- Significant screening ECG abnormalities.
- Pregnancy or breastfeeding.
- Major surgery within 3 weeks before the start of study therapy.
- Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.
- Concurrent participation in another therapeutic or imaging clinical trial.
- Other conditions likely to interfere with a subject's ability to participate in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Dose Level 1
0.75 mg/kg |
SLV-154 |
|
Experimental: Dose Level 2
1.5 mg/kg |
SLV-154 |
|
Experimental: Dose Level 3
3.0 mg/kg |
SLV-154 |
|
Experimental: Dose Level 4
4.0 mg/kg |
SLV-154 |
|
Experimental: Dose Level 5
5.0 mg/kg |
SLV-154 |
|
Experimental: Dose Level 6
6.5 mg/kg |
SLV-154 |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Phase 1a: MTD and/or RDR
Periodo de tiempo: Through the duration of treatment, up to approximately 18 months
|
Determination of the MTD (maximum tolerated dose) and/or RDR (recommended dosing regimen) for SLV-154. |
Through the duration of treatment, up to approximately 18 months
|
|
Phase 1b: Objective response rate (ORR)
Periodo de tiempo: Through the duration of treatment, up to approximately 18 months
|
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR). |
Through the duration of treatment, up to approximately 18 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
SLV-154 administration
Periodo de tiempo: Through the duration of treatment, up to approximately 18 months
|
SLV-154 drug administration as assessed by prescribing records |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Safety
Periodo de tiempo: Through the duration of treatment, up to approximately 18 months
|
Collection of type, frequency, severity, timing of onset, duration, and relationship to study drug of any treatment-emergent adverse events (TEAEs); laboratory abnormalities; vital sign/oxygen saturation abnormalities; adverse electrocardiogram (ECG) findings; DLTs; serious adverse events (SAEs); adverse events of special interest (AESIs); or adverse events (AEs) leading to interruption, modification, or discontinuation of study drug administration. |
Through the duration of treatment, up to approximately 18 months
|
|
Evaluation of use of concomitant medications
Periodo de tiempo: Through the duration of treatment, up to approximately 18 months
|
Type, frequency, and timing of use of supportive care and other concomitant medications |
Through the duration of treatment, up to approximately 18 months
|
|
SLV-154 Pharmacokinetics
Periodo de tiempo: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Evaluation of the pharmacokinetic profile of SLV-154 |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Immunogenicity
Periodo de tiempo: Varying timepoints through the duration of treatment, up to approximately 18 months
|
Measurement of changes in titers of circulating SLV 154-reactive antibodies (as assessed using immunoassay methods) |
Varying timepoints through the duration of treatment, up to approximately 18 months
|
|
Time to Response (TTR)
Periodo de tiempo: Up to approximately 36 months
|
TTR: interval from the start of study drug administration to the first documentation of objective tumor regression |
Up to approximately 36 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to approximately 36 months
|
DOR: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
4-month progression-free survival (PFS4)
Periodo de tiempo: Up to approximately 36 months
|
PFS4: proportion of subjects who are alive and have not experienced disease progression at 4 months after the start of study drug administration |
Up to approximately 36 months
|
|
6-month progression-free survival (PFS6)
Periodo de tiempo: Up to approximately 36 months
|
PFS6: proportion of subjects who are alive and have not experienced disease progression at 6 months after the start of study drug administration |
Up to approximately 36 months
|
|
Time to treatment failure (TTF)
Periodo de tiempo: Up to approximately 36 months
|
TTF: interval from the start of study drug administration to the earliest of the first documentation of disease progression, the permanent cessation of study drug due to an AE, or death from any cause |
Up to approximately 36 months
|
|
Overall survival (OS)
Periodo de tiempo: Up to approximately 36 months
|
OS: interval from the start of study drug administration to death from any cause |
Up to approximately 36 months
|
|
Disease benefit ratio (DBR)
Periodo de tiempo: Up to approximately 36 months
|
DBR: proportion of subjects who experience CR, PR, or stable disease with tumor reduction (SDTR) |
Up to approximately 36 months
|
|
Progression free survival (PFS)
Periodo de tiempo: Up to approximately 36 months
|
PFS: interval from the start of study drug administration to the earlier of the first documentation of disease progression or death from any cause |
Up to approximately 36 months
|
|
Duration of disease benefit (DDB)
Periodo de tiempo: Up to approximately 36 months
|
DDB: interval from the first documentation of objective tumor regression to the earlier of the first documentation of disease progression or death from any cause in subjects with disease benefit |
Up to approximately 36 months
|
|
Percent change in tumor dimensions
Periodo de tiempo: Up to approximately 36 months
|
percent change from baseline in the sum of the longest diameters of non-nodal target lesions and the shortest diameters of nodal target lesions |
Up to approximately 36 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SLV-154-01Tx
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Results will be presented in clinical study reports and publications. Individual participant data will not be shared with other researchers.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .